1. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy
- Author
-
Said Assou, Sabine Traver, E. Scalici, S. Belloc, Delphine Haouzi, T. Al-Edani, Samir Hamamah, Cellules souches normales et cancéreuses, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire Eylau-Unilabs [Neuilly-sur-Seine ] (Clinique Pierre-Cherest), Clinique Pierre Cherest [Neuilly-Sur-Seine], Hôpital Arnaud de Villeneuve [CHRU Montpellier], Développement embryonnaire précoce humain et pluripotence EmbryoPluripotency (UMR 1203), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-CHU Montpellier, and Herrada, Anthony
- Subjects
Pathology ,Ovarian Disorder ,Bioinformatics ,MESH: Genital Neoplasms, Female ,MESH: Pregnancy ,0302 clinical medicine ,MESH: Uterine Diseases ,Pregnancy ,Nucleic Acids ,MESH: Embryonic Development ,Ovarian Diseases ,Uterine Diseases ,0303 health sciences ,030219 obstetrics & reproductive medicine ,Female infertility ,Obstetrics and Gynecology ,Prognosis ,MESH: Ovarian Diseases ,3. Good health ,Cell-Free Nucleic Acids ,Cell-free fetal DNA ,Biomarker (medicine) ,Female ,MESH: Biomarkers, Tumor ,infertility ,Embryo quality ,Infertility ,medicine.medical_specialty ,non-invasive biomarkers ,Genital Neoplasms, Female ,Embryonic Development ,Biology ,MESH: Prognosis ,cell-free DNA ,03 medical and health sciences ,Fetus ,Biomarkers, Tumor ,MESH: Aneuploidy ,medicine ,Humans ,[SDV.BDLR] Life Sciences [q-bio]/Reproductive Biology ,030304 developmental biology ,MESH: Humans ,MESH: Fetus ,[SDV.BDLR]Life Sciences [q-bio]/Reproductive Biology ,Aneuploidy ,MESH: Nucleic Acids ,medicine.disease ,MicroRNAs ,Reproductive Medicine ,MESH: Biomarkers ,MESH: Genital Diseases, Female ,Genital Diseases, Female ,MESH: MicroRNAs ,MESH: Female ,Biomarkers - Abstract
International audience; Background: Proper folliculogenesis is fundamental to obtain a competent oocyte that, once fertilized, can support the acquisition of embryo developmental competence and pregnancy. MicroRNAs (miRNAs) are crucial regulators of folliculogenesis, which are expressed in the cumulus-oocyte complex and in granulosa cells and some can also be found in the bloodstream. These circulating miRNAs are intensively studied and used as diagnostic/prognostic markers of many diseases, including gynecological and pregnancy disorders. In addition, serum contains small amounts of cell-free DNA (cfDNA), presumably resulting from the release of genetic material from apoptotic/necrotic cells. The quantification of nucleic acids in serum samples could be used as a diagnostic tool for female infertility.Methods: An overview of the published literature on miRNAs, and particularly on the use of circulating miRNAs and cfDNA as non-invasive biomarkers of gynecological diseases, was performed (up to January 2014).Results: In the past decade, cell-free nucleic acids have been studied for potential use as biomarkers in many diseases, particularly in gynecological cancers, ovarian and endometrial disorders, as well as in pregnancy-related pathologies and fetal aneuploidy. The data strongly suggest that the concentration of cell-free nucleic acids in serum from IVF patients or in embryo culture medium could be related to the ovarian hormone status and embryo quality, respectively, and be used as a non-invasive biomarker of IVF outcome.Conclusions: The profiling of circulating nucleic acids, such as miRNAs and cfDNA, opens new perspectives for the diagnosis/prognosis of ovarian disorders and for the prediction of IVF outcomes, namely (embryo quality and pregnancy).
- Published
- 2014
- Full Text
- View/download PDF